All news
-
9 Oct 2020
MAD for Cancer on Stage
This November, MAD for Cancer researchers participated in the popular science show ’Om X Antal År’ (in so many years) hosted by Cecilia Nebel and comedian Jesper Rönndal at Medicon...
-
9 Oct 2020
Breast Cancer Association Award 2019
Mårten Fernö and Åke Borg, both breast cancer researchers at Lund University, received the Breast Cancer Association Award 2019. In more than 40 years, the two scientists have deve...
-
9 Oct 2020
Kristian Pietras awarded the Göran Gustafsson Prize
Kristian Pietras, Professor of Molecular Medicine at the Department of Laboratory Medicine, has been awarded the Göran Gustafsson Prize in Medicine for "his breakthrough analysis o...
-
9 Oct 2020
"Wrong" type of connective tissue cells gives worse prognosis for breast cancer
In some cancers, connective tissue is formed around and within the tumor. A hypothesis, which has not been proven so far, is that there are several different types of connective ti...
-
6 Oct 2020
TEDx Lund
Professor Carl Borrebaeck, held an inspiring talk at TEDxLund, www.tedxlund.se, hosted by Medicon Village and MAX IV.
-
2 Oct 2020
Multifocal strategy to fight cancer
Within Mad for Cancer we use a multidisciplinary approach to defeat cancer. We utilize knowledge from research areas such as cancer stem cells, immuno-oncology, tumor micro-environ...
-
1 Oct 2020
Professor Kristian Pietras publish new study in Nature Medicine.
New treatment for aggressive breast cancer
-
18 Sep 2017
Lunds Fernströmpris till forskning om cancercellers samspel med omgivningen
Kristian Pietras, professor i molekylär medicin, har utsetts till Lunds universitets egen Fernströmpristagare. Han får priset för sin banbrytande forskning om samspelet mellan tumö...
-
29 Aug 2017
Improved gene analysis of kidney cancer defines kidney cancer subtypes
Professor Håkan Axelsson and his team have identified a series of gene expression programs that are characteristic for specific cell types of the nephron. This can be used to defin...
-
13 Jun 2016
New variants of blood cancer in children
Prof Thoas Fioretos and his research team has performed a detailed study of leukemia cells from over 200 children and discovered two new subtypes of childhood leukemia.
-
4 May 2016
A breakthrough of professor Kristian Pietras highlighted by Cancerfonden
Pietras and his colleagues recently discovered that high levels of the ALK1 protein is linked to the spread of breast cancer and that there is an opportunity to inhibit this by blo...
-
8 Apr 2016
CREATE Health research in "Cancerfondsrapporten 2016"
Researchers from CREATE Health have been highlighted in an article in the yearly report of the Swedish Cancer Society. The report briefly describes highly interesting studies by Åk...
-
8 Apr 2016
Pancreatic Cancer Nordic Newsletter includes research from CREATE Health
Based on recent results from retrospective studies, that are now under publication, we can differentiate the early resectable stages of pancreatic cancer, stage I and II, from the ...
-
6 Apr 2016
Cantargia receives patent approval in Japan and Mexico
The patent application covers IL1RAP as a target molecule for antibody therapy and leukemia diagnostics. The IL1RAP originates from the research of Prof Thoas Fioretos.
-
23 Mar 2016
Donation ger skjuts åt forskning som tar helhetsgrepp på tumörer
Forskare från fyra fakulteter vid Lunds universitet samlar sin expertkunskap för att studera cancer ur flera perspektiv. Målet är bättre och tidigare metoder för diagnos och behand...
-
16 Feb 2016
US-based Starr Companies made a donation to MAD for Cancer
Recently, the Lund University alumni Bertil P. Lundqvist, made a donation to the MAD for Cancer program, his American employer Starr Companies matched the amount. This procedure i...
-
8 Feb 2016
Minority of cancer cells can contribute to entire tumor growth in pancreatic cancer
Professor Kristian Pietras´ research group together with researchers at Karolinska Institute in Stockholm recently showed that it is only a small minority of tumor cells in neuroen...
-
9 Oct 2015
US Rogosin Institute invests in MAD for Cancer
The US research institute, Rogosin Institute, invests in the Lund-based research program MAD for Cancer.
-
19 Aug 2015
New results for galiellalactone and its effect on prostate cancer
Researchers within MAD for Cancer recently published new results for the promising STAT3 inhibitor galiellalactone and its effect on prostate cancer